Amdocs (NASDAQ: DOX) reported its third quarter of fiscal 2026 results today, and the stock is down roughly 2.5% on the session. The exact quarter-by-quarter print is less interesting right now than what has already happened to the valuation. The stock is down 31% year-to-date and 38% over the past 12 months, having collapsed from a 52-week high of $90.29 to the mid-$50s. That kind of multiple compression on a company that generates nearly $700 million in trailing free cash flow and pays a 4% dividend is the kind of setup where you ask whether the business deterioration has kept pace with the stock decline - or whether the market has overreacted.
The answer, in this case, leans toward the latter.
What the market is reacting to
Amdocs has not been a growth story. Trailing revenue growth sits at -2.7% year-over-year, and constant-currency growth in the last reported quarter was a modest 2.2%. The CEO changed this fiscal year - Shimie Hortig took over from Shuky Sheffer - and CFO Tamar Rapaport-Dagim retired in May, with Tal Rozenfeld stepping in June. A leadership transition in a $5.9 billion company that runs on execution discipline naturally makes investors nervous. Add in the fact that management has been promoting a new product platform called aOS - an "agentic operating system" for telecommunications - and the concern that AI narrative-building might be substituting for revenue growth, and the selloff has a logical explanation.
Quick Backtesting Tool
But explanation is not justification. The question is whether the valuation now reflects enough risk to make the stock actionable.
The operating metrics tell a different story than the stock chart
Free cash flow growth is up 12.8% year-over-year to $678.7 million on a trailing twelve-month basis. That is the metric that actually funds dividends, buybacks, and product investment - and it is growing, not shrinking. AmdocsDOX-- generates roughly $793 million in operating cash flow annually with capital expenditures of just $114 million, which means its cash conversion is tight. Margins are holding. The operating margin sits at 15.7% on a GAAP basis and 20.1% on an EBITDA basis. Gross margin is 37.8%. Return on invested capital is 13.9%. These are not explosive numbers, but they are stable margins on a business model that is roughly two-thirds recurring managed services revenue. Managed services grew 1.6% in the last reported quarter - slow, but not deteriorating.
The twelve-month backlog stands at $4.28 billion, up 2.6% year-over-year. Backlog growth matters for Amdocs because it is a project-driven business; new multi-year deals with carriers like T-Mobile and Vodafone Germany signal that the renewal and expansion engine is intact. The Q1 2026 T-Mobile deal alone was a strategic multi-year agreement covering managed services, software development, and AI innovation.
On the earnings side, both Q1 and Q2 of fiscal 2026 beat consensus EPS expectations and came in above guidance midpoints. Q2 non-GAAP diluted EPS was $1.78, above the midpoint of the $1.73-$1.79 guidance range. For Q3, analysts were expecting roughly $1.84 per share in earnings and $1.175 billion in revenue - within the company's own guidance range of $1.155-$1.195 billion for revenue and $1.81-$1.87 for non-GAAP EPS.
The valuation is the bridge
This is where the math works for buyers. The stock trades at 10.8 times trailing earnings, 9.4 times forward earnings, and 7.0 times EV/EBITDA. By comparison, Cognizant (NASDAQ: CTSH) - a larger IT services peer with similar margin profiles - trades at 11.3 times trailing earnings and 6.4 times EV/EBITDA. Amdocs is not commanding a premium; it is trading at or below peer multiples while paying a substantially higher dividend.
That 4.0% dividend yield is the floor that changes the risk/reward calculation. The payout ratio sits at roughly 53% of trailing earnings, which is sustainable given the free cash flow coverage. The company also repurchased $146 million in Q1 and $138 million in Q2, returning more than 100% of free cash flow to shareholders through the combination of dividends and buybacks. A debt-to-equity ratio of 26% and $214 million in cash means the balance sheet can absorb this capital return policy even in a soft quarter.
At 9.4 times forward earnings with a 4% yield, the market is pricing Amdocs as if growth is permanently gone and margins are at risk. But the operational evidence - growing FCF, stable margins, beating guidance, expanding backlog - does not support that level of pessimism. Even if revenue growth stays in the low-single-digits, earnings growth of 4-7% on operating leverage plus a 4% dividend gives a total return profile that is hard to match at this multiple.
What to watch next
The aOS platform is the wildcard. Management has positioned it as a "new long-term growth engine," and the company has initial commercial engagements. But the distinction between early pilot deals and material revenue contribution is enormous. Right now, aOS is a narrative, not a financial line item. Investors should listen to the Q3 conference call for any concrete evidence of aOS bookings converting into contract value or margin impact. If management can point to specific customers, deal sizes, or margin leverage, the AI story moves from promotional to investable. If the discussion stays at the roadmap level, treat it as optionality, not a catalyst.
The broader risk is execution under new leadership. Two C-suite changes in six months is a lot of institutional memory to replace. The company's business depends on long-cycle project delivery for major carriers - AT&T, Vodafone, Verizon, Telstra - and any slippage on flagship implementations would erode the margin stability that currently supports the thesis. Full-year fiscal 2026 free cash flow guidance of $710-$730 million (excluding restructuring payments) sets a bar; missing that range would be a genuine red flag.
Rating: Buy
The selloff has done the valuation reset. The business has not deteriorated at anywhere near the pace of the stock decline. Amdocs at $55, with 9.4x forward earnings, 7.0x EV/EBITDA, growing free cash flow, stable margins, and a 4% dividend yield, offers a risk/reward skew that favors the buyer. The growth rate is modest - that is the known risk, and the multiple now reflects it. The next two quarters will test whether the new leadership team can keep guidance execution intact and whether aOS shows any traction beyond the press release. If the company continues to meet guidance and maintain free cash flow in the $700 million range, the current price is a discount to what the fundamentals deserve.
